经手术切除标本穿刺获得的导管原位癌样本的微阵列分析。
Microarray analysis of ductal carcinoma in situ samples obtained by puncture from surgical resection specimens.
机构信息
Department of Endocrine Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Department of Breast Surgery, Nippon Medical School Musashi Kosugi Hospital, 1-396 Kosugi-cho, Nakahara-ku, Kawasaki, 211-8533, Japan.
出版信息
BMC Res Notes. 2021 Aug 30;14(1):340. doi: 10.1186/s13104-021-05760-z.
Abstract
OBJECTIVE
The incidence of ductal carcinoma in situ (DCIS) is increasing due to more widespread mammographic screening. DCIS, the earliest form of breast cancer, is non-invasive at the time of detection. If DCIS tissues are left undetected or untreated, it can spread to the surrounding breast tissue. Thus, surgical resection is the standard treatment. Understanding the mechanism underlying the non-invasive property of DCIS could lead to more appropriate medical treatments, including nonsurgical options.
DATA DESCRIPTION
We conducted a microarray-based genome-wide transcriptome analysis using DCIS specimens obtained by puncture from surgical specimens immediately after surgery.
摘要
目的
由于更广泛的乳房 X 线筛查，导管原位癌（DCIS）的发病率正在增加。DCIS 是乳腺癌的最早形式，在检测时是非浸润性的。如果 DCIS 组织未被发现或未得到治疗，它可能会扩散到周围的乳腺组织。因此，手术切除是标准的治疗方法。了解 DCIS 非浸润性特性的机制可能会导致更合适的治疗方法，包括非手术选择。
数据描述
我们使用手术标本切除后立即通过穿刺获得的 DCIS 标本进行了基于微阵列的全基因组转录组分析。
相似文献
1
Microarray analysis of ductal carcinoma in situ samples obtained by puncture from surgical resection specimens.经手术切除标本穿刺获得的导管原位癌样本的微阵列分析。
BMC Res Notes. 2021 Aug 30;14(1):340. doi: 10.1186/s13104-021-05760-z.
2
Ductal Carcinoma In Situ - Quo Vadis?导管原位癌——路在何方？
Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S5-S6.
3
Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.原位、浸润性和淋巴管血管侵犯乳腺癌之间差异 microRNA 表达谱分析：一项初步研究。
Clin Exp Metastasis. 2018 Feb;35(1-2):3-13. doi: 10.1007/s10585-017-9868-4. Epub 2017 Dec 6.
4
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.有证据表明，在乳腺导管癌进展过程中，细胞的分子变化先于形态学改变出现。
Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.
5
Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.英国国民保健署筛查性导管原位癌审计中对筛查性 DCIS 腋窝管理的变化：来自英国国民保健署乳腺筛查计划审计的证据。
Eur J Surg Oncol. 2015 Jan;41(1):86-93. doi: 10.1016/j.ejso.2014.09.003. Epub 2014 Oct 16.
6
An extracellular matrix stiffness-induced breast cancer cell transcriptome resembles the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).细胞外基质硬度诱导的乳腺癌细胞转录组类似于从原位导管癌（DCIS）到浸润性导管癌（IDC）的转变。
Biochem Biophys Res Commun. 2023 Apr 30;654:73-79. doi: 10.1016/j.bbrc.2023.03.001. Epub 2023 Mar 2.
7
Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.体内导管原位癌进展模型的表达谱分析确定B细胞淋巴瘤-9是乳腺癌侵袭的分子驱动因素。
Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.
8
Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery.在经活检证实的原位导管癌中，假定的肿瘤抑制基因NES1的表达缺失预示着在根治性手术时会出现浸润性癌。
Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):653-7. doi: 10.1016/s0360-3016(03)00068-3.
9
What should be the width of radiological margin to optimize resection of non-palpable invasive or in situ ductal carcinoma?为优化不可触及的浸润性或原位导管癌的切除，放射学切缘宽度应为多少？
Breast. 2014 Dec;23(6):889-93. doi: 10.1016/j.breast.2014.10.001. Epub 2014 Oct 23.
10
Gene amplification in ductal carcinoma in situ of the breast.乳腺导管原位癌中的基因扩增。
Breast Cancer Res Treat. 2010 Oct;123(3):757-65. doi: 10.1007/s10549-009-0675-8. Epub 2009 Dec 22.
引用本文的文献
1
an Immune-Related Long Non-Coding RNA Associated with Early-Stage Breast Cancer Progression.一种与早期乳腺癌进展相关的免疫相关长链非编码RNA。
Cancers (Basel). 2022 Jun 7;14(12):2819. doi: 10.3390/cancers14122819.
2
RNA recovery from specimens of duct-washing cytology performed contemporaneously with mammary ductoscopy.从同期进行的乳腺导管镜检查的导管冲洗细胞学标本中回收 RNA。
BMC Res Notes. 2022 Feb 10;15(1):34. doi: 10.1186/s13104-022-05928-1.
本文引用的文献
1
Microarray analysis of formalin-fixed, paraffin-embedded follicular thyroid carcinoma samples from patients who developed postoperative distant metastasis.对术后发生远处转移的滤泡状甲状腺癌患者的福尔马林固定石蜡包埋样本进行微阵列分析。
BMC Res Notes. 2020 May 13;13(1):241. doi: 10.1186/s13104-020-05080-8.
2
Proteinase K treatment improves RNA recovery from thyroid cells fixed with liquid-based cytology solution.蛋白酶K处理可提高从经液基细胞学溶液固定的甲状腺细胞中回收RNA的效率。
BMC Res Notes. 2018 Nov 20;11(1):822. doi: 10.1186/s13104-018-3914-4.
3
Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.导管原位癌诊断后的乳腺癌死亡率。
JAMA Oncol. 2015 Oct;1(7):888-96. doi: 10.1001/jamaoncol.2015.2510.
4
Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study.低级别导管原位癌行乳腺手术的生存获益：基于人群的队列研究。
JAMA Surg. 2015 Aug;150(8):739-45. doi: 10.1001/jamasurg.2015.0876.
5
Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.乳腺导管原位癌的核心针活检：低估的荟萃分析和浸润性乳腺癌的预测因素。
Radiology. 2011 Jul;260(1):119-28. doi: 10.1148/radiol.11102368. Epub 2011 Apr 14.
6
The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.仅接受活检治疗的女性乳腺导管原位癌的自然病史在超过30年的长期随访中得以揭示。
Cancer. 2005 Jun 15;103(12):2481-4. doi: 10.1002/cncr.21069.
7
Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.诊断性活检后未经治疗的导管原位癌患者的结局：护士健康研究的结果。
Cancer. 2005 May 1;103(9):1778-84. doi: 10.1002/cncr.20979.
8
The treatment of in situ breast cancer.原位乳腺癌的治疗
Acta Oncol. 1989;28(6):923-6. doi: 10.3109/02841868909092333.
Zotero 插件